Bramlage Lifesciences is an investment company of the physician and entrepreneur Prof. Dr. Peter Bramlage.
We invest long-term in life sciences companies and work in partnership to support their entrepreneurial success.
Bramlage Lifesciences is an investment company of the physician and entrepreneur Prof. Dr. Peter Bramlage.
We invest long-term in life sciences companies and work in partnership to support their entrepreneurial success.
“We believe that companies become successful when they pursue meaningful goals.”
Peter Bramlage began his medical training at Justus Liebig University in Giessen. During this time, he also studied at the universities of Vienna (Austria) and Columbia (Missouri, USA). He received his doctorate at the Max Planck Institute for Physiological and Clinical Research in Bad Nauheim.
His professional career has included positions at the Charité University Hospital – Campus Mitte in the Department of Cardiology and Angiology, the pharmaceutical company Sanofi, and the Institute of Clinical Pharmacology at the Technical University of Dresden. Peter Bramlage is an active member of the German Cardiac Society (DGK) and a Fellow of the European Society of Cardiology (FESC).
For more than 20 years, Peter Bramlage has been active as an entrepreneur in clinical research. During this time, he has founded several companies, continued the development of others, and invested in multiple businesses. In these roles, he contributes both business acumen and scientific expertise to the success of these ventures.
We are committed to the medical and scientific objectives of the companies in which we invest. At the same time, we ensure that their financing and economic sustainability support the achievement of these strategic goals. On a personal level, we work closely, sustainably, and with mutual trust with the managing directors, fellow shareholders, and employees of our portfolio companies, guided by clear governance principles.
Our companies develop and market products and provide services that sustainably improve the health of many people.
Responsible conduct—guided by medical and ethical principles—is therefore at the core of our strategy and decision-making.
We invest in companies with the goal of sustainably increasing their reach and value. Speculative short-term buying or selling is generally not part of our approach.
Personal conversations form the foundation of our collaborative partnerships.
For this reason, we primarily invest in Germany, Austria, and Switzerland, as well as in neighboring European countries.
BLS initially prefers to acquire significant minority stakes (more than 25% of voting rights). If the chemistry is right and the shareholders desire deeper involvement, we are open to exploring that as well.
In addition, we are interested in founder teams and pioneering ideas. A small stake can serve as a starting point for validating a broader strategic collaboration.
Our portfolio companies retain their independence. At the same time, we work synergistically within the group, and the companies support one another. This approach allows each company to pursue its individual focus while benefiting from shared experience.
| Company | Location | Sector | Since | Stake |
|---|---|---|---|---|
|
Cloppenburg |
Cardiovascular Clinical Research |
2011 |
100% |
|
|
Berlin |
Healthcare IT |
2015 |
100% |
|
|
Heidelberg |
Digital Health |
2022 |
Majority |
|
|
Ludwigshafen |
Cardiovascular Clinical Research |
2024 |
100% |
|
| Company | Location | Sector | Since | Stake |
|---|---|---|---|---|
|
Berlin |
Pharmaceuticals |
2025 |
Minority |
|
|
Berlin |
Digital Health / OTC |
2023 |
Minority |
|
|
Heidelberg |
Medical Devices |
2023 |
Minority |
|
|
Potsdam |
Medical Devices |
2022 |
Minority |
|
|
Regensburg |
Medical Devices |
2021 |
Minority |
Claudia assumed management of IPPMed GmbH, a company specializing in research projects for cardiovascular indications, at a young age. With her deep hands-on expertise, she has been a key contributor to the company’s current success. She also supports the exchange of best practices across the group of companies.
Arne has had a diverse career, with roles in medical marketing within the pharmaceutical industry and in implementing strategic directives as managing director of healthcare agencies. In addition to leading IHF GmbH, he is responsible for the external communications of the corporate group.
Philippe is a healthcare and IT entrepreneur with experience in founding companies, executive management, B2B sales, and the divestment of business stakes. He ensures active knowledge sharing and the realization of synergies among the group’s portfolio companies.
Felix founded Midaia GmbH several years ago and has developed it into an award-winning company in rheumatology data acquisition and clinical research. He stays closely attuned to the latest developments in patient-centered healthcare applications.
Kai is the steady force guiding the direction of Software for Trials Europe GmbH with reliability and focus. After positions in the food industry, he has spent several years supporting the development of young companies within and alongside the group.
